Abstract | BACKGROUND AND AIMS: DESIGN AND METHODS: Forty-eight IGT or type 2 DM (T2DM) patients were assigned to receive either pioglitazone (n=29) or glimepiride (n=19) and evaluated at baseline and 16 weeks of follow-up. We compared the effects of pioglitazone and glimepride on ADMA and soluble form of RAGE (sRAGE) levels and then studied whether the changes in serum ADMA level (ΔADMA) after treatment with pioglitazone were correlated with ΔsRAGE. We further examined which Δclinical variables were independently associated with ΔADMA. RESULTS: CONCLUSIONS:
|
Authors | Nobuhiro Tahara, Sho-ichi Yamagishi, Minori Mizoguchi, Atsuko Tahara, Tsutomu Imaizumi |
Journal | Rejuvenation research
(Rejuvenation Res)
Vol. 16
Issue 5
Pg. 344-51
(Oct 2013)
ISSN: 1557-8577 [Electronic] United States |
PMID | 23777507
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fibronectins
- Sulfonylurea Compounds
- Thiazolidinediones
- N,N-dimethylarginine
- glimepiride
- Arginine
- Pioglitazone
|
Topics |
- Aged
- Aged, 80 and over
- Arginine
(analogs & derivatives, blood)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Female
- Fibronectins
(blood)
- Glucose Intolerance
(blood, drug therapy)
- Humans
- Male
- Middle Aged
- Pioglitazone
- Regression Analysis
- Sulfonylurea Compounds
(pharmacology, therapeutic use)
- Thiazolidinediones
(therapeutic use)
|